Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Smartwise
Tullinge, Sweden
- Ownership
- Private
- Development stage
- Other
01
Overview
Smartwise developed and commercialized Extroducer, an FDA-cleared endovascular micro-catheter for direct-to-tissue drug, gene, and cell delivery. The device is used in clinical trials (notably with XyloCor's gene therapy) and approved for direct organ/tissue access in the US, enabling targeted, minimally invasive delivery for therapies including gene, cell, and small molecule drugs. Published clinical collaborations and licensing agreements validate improved targeting, safety, and efficacy over traditional surgical approaches.[1][2][5]
- Therapeutic areas
- OncologyDermatologyCardiovascular
- Modalities
- Device
- Industry
- Surgical Medical Devices
02
Partnerships
Beyond the preview
Go deeper on Smartwise.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Smartwise.